Patents by Inventor Tomas Cihlar

Tomas Cihlar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of phosphonate nucleotide analogues
    Publication number: 20030219727
    Abstract: A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity.
    Type: Application
    Filed: June 16, 2003
    Publication date: November 27, 2003
    Inventors: Mark W. Becker, Harlan H. Chapman, Tomas Cihlar, Eugene J. Eisenberg, Gong-Xin He, Michael R. Kernan, William A. Lee, Ernest J. Prisbe, John C. Rohloff, Mark L. Sparacino
  • Novel gene encoding organic anion transporter
    Publication number: 20030106075
    Abstract: This invention is concerned with human organic anion transporter (“hOAT”). Isolated nucleic acid encoding hOAT is provided, along with ioslated hOAT polypeptide. hOAT nucleic acid and/or hOAT polypeptide are employed in transgenic animals, recombinant cells, replicable vectors and analytical procedures for identifying hOAT agonists or antagonists, assays for identifying hOAT alleles and/or isotypes, screening tests for nephrotoxic or neurologically active compounds, and determination of drug-drug interactions within the kidney or brain.
    Type: Application
    Filed: February 28, 2002
    Publication date: June 5, 2003
    Inventor: Tomas Cihlar
  • Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1 (hOAT1)
    Patent number: 6479231
    Abstract: Secretion of small molecules from systemic blood circulation into urine is one of the physiologically essential functions of the kidney. Human organic anion transporter (hOAT1) is a key component in the renal tubular secretion of negatively charged molecules including a variety of important therapeutics. In some cases, compounds interacting with hOAT1 may induce pharmacokinetic drug-drug interactions or cause nephrotoxicity. We developed a fluorescence-based, 96-well format assay using CHO cells stably expressing hOAT1, which allows for the evaluation of interactions between small molecules and hOAT1. The assay is based on the inhibition of the transport of 6-carboxyfluorescein, a high-affinity hOAT1 substrate (Km=3.9 &mgr;M), which was identified among several other fluorescent organic anions.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: November 12, 2002
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
    Publication number: 20020119443
    Abstract: A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity.
    Type: Application
    Filed: July 20, 2001
    Publication date: August 29, 2002
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Mark W. Becker, Harlan H. Chapman, Tomas Cihlar, Eugene J. Eisenberg, Gong-Xin He, Michael R. Kernan, William A. Lee, Ernest J. Prisbe, John C. Rohloff, Mark L. Sparacino
  • Gene encoding organic anion transporter
    Patent number: 6432631
    Abstract: This invention is concerned with human organic anion transporter (“hOAT”). Isolated nucleic acid encoding hOAT is provided, along with isolated hOAT polypeptide. hOAT nucleic acid and/or hOAT polypeptide are employed in transgenic animals, recombinant cells, replicable vectors and analytical procedures for identifying hOAT agonists or antagonists, assays for identifying hOAT alleles and/or isotypes, screening tests for nephrotoxic or neurologically active compounds, and determination of drug-drug interactions within the kidney or brain.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: August 13, 2002
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar